Rhythm Pharmaceuticals
RYTM
203 hedge funds and large institutions have $3.63B invested in Rhythm Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 52 funds opening new positions, 66 increasing their positions, 53 reducing their positions, and 24 closing their positions.
1,417% more call options, than puts
Call options by funds: $26.8M | Put options by funds: $1.76M
117% more first-time investments, than exits
New positions opened: 52 | Existing positions closed: 24
25% more repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 53
15% more funds holding
Funds holding: 176 → 203 (+27)
10% more funds holding in top 10
Funds holding in top 10: 10 → 11 (+1)
2% more capital invested
Capital invested by funds: $3.55B → $3.63B (+$88M)
5.12% less ownership
Funds ownership: 110.75% → 105.63% (-5.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$34.3M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$15.8M |
| 3 |
JP Morgan Chase
New York
|
+$10.1M |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$9.81M |
| 5 |
SC
Stempoint Capital
New York
|
+$9.21M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$114M |
| 2 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
-$58.2M |
| 3 |
Primecap Management
Pasadena,
California
|
-$35.7M |
| 4 |
CC
Commodore Capital
New York
|
-$34.1M |
| 5 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
-$30.2M |
RYTM Hedge Fund Activity: Q4 2024 in Review
203 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Rhythm Pharmaceuticals (RYTM) for Q4 2024, worth a combined $3.63B — up 2.5% from $3.55B a quarter earlier.
Buyers outnumbered sellers: 52 funds opened new RYTM positions and 24 closed out — a net gain of 28 holders — while 66 added to existing stakes and 53 trimmed.
The largest buyer was Janus Henderson Group, adding an estimated $34.3M. The largest seller was Goldman Sachs, cutting an estimated $114M.
- 203 institutional investors held Rhythm Pharmaceuticals (RYTM) as of Q4 2024, up from 176 in Q3 2024.
- Funds reported $3.63B of Rhythm Pharmaceuticals stock for Q4 2024, up 2.5% quarter-over-quarter.
- 52 funds opened new Rhythm Pharmaceuticals positions in Q4 2024 and 24 closed out, a net change of +28 holders.
- The largest Rhythm Pharmaceuticals buyer in Q4 2024 was Janus Henderson Group, an estimated $34.3M added.
- The largest Rhythm Pharmaceuticals seller in Q4 2024 was Goldman Sachs, an estimated $114M sold.
Based on aggregated 13F filings for Q4 2024.